MGX Dana dhuwit perusahaan Metagenomi

Tandha merek Metagenomi Inc. (MGX)

High early-stage risks and a lack of revenue make Metagenomi, Inc. (MGX) dependent on capital. This cash accumulation chart visualizes current liquidity, where the 0.10 mark indicates the current state of resources. The business relies on searching for natural enzymes to bypass patents, and the project's success is based on technology protection and progress in preclinical research.

MGX - Posisi dhuwit perusahaan Metagenomi Therapeutics ing rentang 21.02.2024 - 21.11.2026

Metagenomi Inc. (MGX) - rincian metrik lan laporan keuangan

- rega saiki lan proyeksi nilai saham:
Ringkesan analitik perusahaan:Metagenomi Therapeutics
Produk merek Metagenomi

To assess the long-term sustainability of Metagenomi, Inc. (MGX), investors must analyze the volume of liquid assets, which determines the company's ability to fund R&D without emergency equity issuance. This operational cash figure reflects the cash balance at the end of the session, which is critical for a CRISPR genome-editing startup where high licensing costs necessitate a significant capital reserve before reaching the stage of commercial profitability.

Analisis perusahaan pesaing

Volume dana dhuwit perusahaan TEM|QGEN - Cadangan dhuwit perusahaan|ionispharma.com - Dhuwit awis perusahaan|Sisa dhuwit perusahaan RGEN|Avidity Corp - Volume dana dhuwit perusahaan|CRISPR Therapeutics Corp - Gunggung dana dhuwit perusahaan|GeneDx Holdings (WGS) - Dana dhuwit perusahaan|Ultragenyx Pharmaceutical (RARE) - Volume dana dhuwit perusahaan|Dhuwit awis perusahaan BEAM|Sarepta (SRPT) - Aset likuid perusahaan|Dana dhuwit perusahaan Twist Bioscience Corp (TWST)|10x - Dhuwit awis lan setara dhuwit awis perusahaan|Volume dana dhuwit perusahaan NTLA (intelliatx.com)|Gunggung dana dhuwit perusahaan STOK (stoketherapeutics.com)|BioLife Solutions Inc - Volume dana dhuwit perusahaan|WVE (Wave Life Sciences Ltd) - Dhuwit awis lan setara dhuwit awis perusahaan|Maze Therapeutics Corp (MAZE) - Dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan SION|PRME (Prime Medicine Inc) - Volume dana dhuwit perusahaan|Taysha Gene Therapies (TSHA) - Aset likuid perusahaan|Dhuwit awis perusahaan QURE (uniqure.com)|Gunggung dana dhuwit perusahaan MGTX|Volume dana dhuwit perusahaan RGNX (regenxbio.com)|SLDB: Dhuwit awis lan setara dhuwit awis perusahaan|ocugen.com - Volume dana dhuwit perusahaan|PACB - Volume dana dhuwit perusahaan|BNTC: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan DSGN|Dana dhuwit perusahaan Rocket Pharmaceuticals|Dhuwit awis perusahaan 4DMT (FDMT)|Volume dana dhuwit perusahaan LXEO|Aset likuid perusahaan Korro Bio Inc.|Volume dana dhuwit perusahaan EDIT (Editas Medicine Inc)|SLN: Dhuwit awis lan setara dhuwit awis perusahaan|PRQR - Dana dhuwit perusahaan|Aset likuid perusahaan codexis.com CDXS|SGMO: Volume dana dhuwit perusahaan|Nautilus Biotechnology (NAUT) - Volume dana dhuwit perusahaan|DTIL (Precision BioSciences Inc.) - Volume dana dhuwit perusahaan|generationbio.com (GBIO) - Aset likuid perusahaan|Dana dhuwit perusahaan Boundless Bio Inc (BOLD)|Volume dana dhuwit perusahaan Exicure Inc. (XCUR)|Dana dhuwit perusahaan imunon.com IMNN|Volume dana dhuwit perusahaan Phio Pharmaceuticals PHIO|Mustang Bio Inc - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan transcodetherapeutics.com|BNGO: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan APDN|BLUE (bluebirdbio.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan ImmunoPrecise Antibodies IPA|Dhuwit awis perusahaan OMGA (omegatherapeutics.com)|Volume dana dhuwit perusahaan Singular Genomics Systems, Inc. (OMIC)|Volume dana dhuwit perusahaan RGLS (Regulus Therapeutics, Inc.)|Volume dana dhuwit perusahaan Syros SYRS|Telesis Bio, Inc. - Volume dana dhuwit perusahaan|TRACON Pharmaceuticals (TCON) - Dhuwit awis perusahaan|UBX: Volume dana dhuwit perusahaan